Nubeqa (darolutamide) works in the presence of significant testosterone because it is an androgen receptor (AR) inhibitor, not a testosterone-reducing drug. It blocks testosterone's ability to stimulate prostate cancer cell growth by binding to the androgen receptor and preventing testosterone from attaching.

There are quite a few people in the Weekly ancan.org Advanced prostate cancer meetings that are only on Nubeqa. Most of them are older, and they really like the results since ADT can be difficult.